# A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

> **NCT00358683** · PHASE3 · WITHDRAWN · sponsor: **UCB Pharma**

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Certolizumab pegol

## Key facts

- **NCT ID:** NCT00358683
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358683, "A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00358683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*